Relationship between the expression of complement inhibitory proteins and therapeutic efficacy of antibodies in breast cancer

Montalvo-Castro, Rebeca E.; Salinas-Jazmín, Nohemí

doi:10.24875/gmm.m22000657

Cited by 3 publications

(5 citation statements)

References 35 publications

(101 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding was further substantiated using specific inhibitors (SB, SP, and PD), while SFN treatment hindered the signaling of p38 MAPK/AP-1 and STAT3. The tumor microenvironment significantly influences the expression of membrane-bound complement regulatory proteins (mCRPs) in tumor cells, contributing to tumor immune evasion [69,70]. Several studies have established that mCRPs are highly expressed in colon cancer [71][72][73].…”

Section: Discussionmentioning

confidence: 99%

Sulforaphane Inhibits IL-1β-Induced IL-6 by Suppressing ROS Production, AP-1, and STAT3 in Colorectal Cancer HT-29 Cells

Sah,

Arjunan,

Park

et al. 2024

Antioxidants

View full text Add to dashboard Cite

Colorectal cancer (CRC) stands as a major cause of cancer-related mortality globally, accounting for approximately 881,000 deaths each year. Traditional approaches such as chemotherapy and surgery have been the primary treatment modalities, yet the outcomes for patients with metastatic CRC are often unsatisfactory. Recent research has focused on targeting the pathways involved in oxidative stress, inflammation, and metastasis to enhance the survival of CRC patients. Within this context, sulforaphane (SFN), a notable phytochemical found predominantly in cruciferous vegetables, has been recognized as a potential anticancer agent. However, the specific mechanisms through which SFN may exert its chemopreventive effects in CRC remain unclear. This study explores the impact of SFN on IL-1β-induced IL-6 activation and MAPK and AP-1 signaling in HT-29 cells. Our findings reveal that SFN treatment not only diminishes IL-1β-stimulated IL-6 expression but also reduces oxidative stress by curtailing reactive oxygen species (ROS) production. Furthermore, it hinders the proliferation and invasiveness of HT-29 cells through the modulation of MAPK/AP-1 and STAT3 signaling pathways. These results indicate that SFN mitigates IL-1β-induced IL-6 expression in CRC cells by attenuating ROS production and disrupting MAPK/AP-1 signaling. This suggests that SFN holds significant potential as a chemotherapeutic agent for both treating and preventing CRC.

show abstract

Section: Discussionmentioning

confidence: 99%

Sulforaphane Inhibits IL-1β-Induced IL-6 by Suppressing ROS Production, AP-1, and STAT3 in Colorectal Cancer HT-29 Cells

Sah,

Arjunan,

Park

et al. 2024

Antioxidants

View full text Add to dashboard Cite

show abstract

“…Furthermore, IgM antibodies can effectively activate the classical complement pathway because, unlike IgG, a single molecule of IgM can bind to C1q and initiate the proteolytic cascade [9,22]. However, the activation of the classical pathway through IgG antibodies in breast cancer is not excluded, as is the case with therapeutic antibodies [5,12]. The presence of IgG, C3, and C4 together with deposits of C5b-9 complexes on tumor cell membranes, were observed in samples Membrane-Bound Complement Regulatory Proteins in Breast Cancer: Are they Best Therapeutic… DOI: http://dx.doi.org/10.5772/intechopen.109945 from breast cancer patients, indicating a persistent in situ complement activation [23].…”

Section: Complement Activation By Tumor Cellsmentioning

confidence: 99%

“…But these proteins also can regulate non-complement signaling in promoting cancer proliferation, chemoresistance, and metastasis. We proposed a model of signaling pathways activated by mCRP [12] and recently Bharti et al also proposed a series of pathways intracellularly by CD55 [43]. Due to their relevance in the potential of anticancer antibodies, they have been proposed and studied mCRP as therapeutic targets through various models and strategies: small interfering RNAs (siRNA) [69,71,84,85], antibodies anti-mCRP [13], and enzyme-peptide [13,86].…”

Section: Therapeutic Strategies and Future Challenges To Regulate Mcr...mentioning

confidence: 99%

See 1 more Smart Citation

Membrane-Bound Complement Regulatory Proteins in Breast Cancer: Are They Best Therapeutic Targets?

Álvarez-Lorenzo¹,

Montalvo-Castro²,

Jiménez-López³

et al. 2023

Breast Cancer Updates

Self Cite

View full text Add to dashboard Cite

Breast cancer is one of the most aggressive diseases in women, responsible for thousands of deaths annually and millions of new diagnoses; its treatment presents multiple obstacles due to late diagnosis and the various mechanisms of tumor resistance. In breast cancer the membrane-bound complement regulatory proteins (mCRP) have been proposed as biomarkers of malignant cellular transformation. These are molecules capable of inhibiting therapeutic efficacy, from both antibodies and cytotoxic drugs. Therefore, these proteins are potential targets to increase therapeutic efficacy and avoid cancer progression. We will gather information about mCRP: (i) structural features; (ii) expression levels in breast cancer and relationship with prognosis; (iii) therapeutic resistance mechanisms; and (iv) strategies to down-regulate mCRP in both activity and expression.

show abstract

“…Breast cancer is the most common female cancer ( Di Modica et al, 2022 ; Zhang H. et al, 2022 ), with a mortality rate second only to that of lung cancer, especially since the International Agency for Research on Cancer recently found that the mortality rate for breast cancer has now gradually surpassed that of lung cancer ( Pearanpan et al, 2022 ; Yamashita and Kufe, 2022 ). Triple-negative breast cancer is highly malignant and difficult to treat ( Hacking et al, 2022 ; Montalvo-Castro and Salinas-Jazmín, 2022 ). Although chemotherapy, radiation therapy, and systemic immunotherapy have led to longer survival, some patients with advanced breast cancer develop metastatic cancer ( Gautam et al, 2022 ; Karn et al, 2022 ).…”

Section: Salvianolic Acid Bmentioning

confidence: 99%

Salvianolic acid B from Salvia miltiorrhiza bunge: A potential antitumor agent

Guo

Wang

2022

Front. Pharmacol.

View full text Add to dashboard Cite

Salvia miltiorrhiza Bunge (Lamiaceae) is a perennial herb widely found in China since ancient times with a high economic and medicinal value. Salvianolic acid B (Sal-B) is an important natural product derived from Salvia miltiorrhiza and this review summarizes the anticancer activity of Sal-B. Sal-B inhibits tumor growth and metastasis by targeting multiple cell signaling pathways. This review aims to review experimental studies to describe the possible anticancer mechanisms of Sal-B and confirm its potential as a therapeutic drug.

show abstract

Relationship between the expression of complement inhibitory proteins and therapeutic efficacy of antibodies in breast cancer

Cited by 3 publications

References 35 publications

Sulforaphane Inhibits IL-1β-Induced IL-6 by Suppressing ROS Production, AP-1, and STAT3 in Colorectal Cancer HT-29 Cells

Sulforaphane Inhibits IL-1β-Induced IL-6 by Suppressing ROS Production, AP-1, and STAT3 in Colorectal Cancer HT-29 Cells

Membrane-Bound Complement Regulatory Proteins in Breast Cancer: Are They Best Therapeutic Targets?

Salvianolic acid B from Salvia miltiorrhiza bunge: A potential antitumor agent

Contact Info

Product

Resources

About